Statement: Only White and Asian patients are eligible for both the primary trial and the secondary trial.
Primary_evidence: Inclusion Criteria:   Diagnosis of breast cancer   Part 1 only: Surgery for breast cancer within the past eight weeks (mastectomy or lumpectomy with either sentinel or axillar dissection), including those women with a history of previous surgery for breast cancer, radiation therapy or chemotherapy   Part 2 only: Completion of surgery and radiation therapy for breast cancer within the past six weeks.   Home access to internet from stationary computer, lab top or tablet   Ability to use internet   Ability to read and understand Danish Exclusion Criteria:   Surgery for breast cancer with immediate breast reconstruction   Diagnosis of primary lymphedema   Metastatic or inflammatory breast cancer   Planned use of chemotherapy within the next 6 weeks   Surgical complications: infection, drainage issues, seroma, hematoma   Severe physical, cognitive, or psychiatric illness causing inability to follow the study protocol: i.e. severe depression, anxiety, dementia, poor physical health with likely possibility of hospitalization within the next twelve weeks.   Planned hospitalization or surgery within the next twelve weeks   Participation in another clinical trial with a rehabilitation or exercise intervention
Secondary_evidence: Inclusion Criteria:   Female with a diagnosis of, non-inflammatory breast adenocarcinoma and be referred for post-operative radiotherapy without concurrent chemotherapy.   Participants must be at least 21 years of age.   Participants must not be pregnant.   Participants can be from any racial or ethnic origin.   Breast adenocarcinoma could have been treated by either lumpectomy or mastectomy with or without adjuvant or neoadjuvant chemotherapy or hormonal treatment.   Participants with in situ breast cancer are eligible.   Participants who are prescribed concurrent hormone treatment with radiation treatment are eligible.   Participants must be scheduled to receive five sessions of radiation therapy per week (1 session per day) for at least four weeks using standard (1.8-2.0 Gy per session)or Canadian (2.2-2.5 Gy per session)irradiation fractionation.   A time period of three weeks must elapse after chemotherapy and surgery before beginning the study.   The total dose prescribed to the whole breast should be 50 Gy or greater.   Participants must be able to understand English and able to complete assessment forms (all assessment forms are in English).   Participants must be able to swallow medication.   Topical skin agents, e.g., Aquaphor, Cetaphil, or other emollients, are allowed either PRN or prophylactically.   Participant must give informed consent. Exclusion Criteria:   Patients with bilateral breast cancer are not eligible.   Patients who have had previous radiation therapy to the breast or chest are not eligible.   Patients who are prescribed chemotherapy concurrently with radiation treatment are not eligible.   Patients who will be receiving treatment with Herceptin (trastuzumab), anti-coagulants, or anti-human epidermal growth factor receptor (EGFR) drugs, e.g. Iressa (gefitinib), Erbitux (cetuximab, C225), concurrently with their radiation therapy are not eligible.   Patients cannot have had breast reconstructions, implants, and/or expanders.   Patients with known radiosensitivity syndromes (e.g., Ataxia-telangiectasia) are not eligible.   Patients with collagen vascular disease, vasculitis, unhealed surgical sites, or breast infections are not eligible.   Patients whose baseline blood tests meet the following criteria are not eligible: greater than or equal to Grade 2 change Hemoglobin (i.e., 25% decrease from baseline); greater than or equal to Grade 1 change in Platelets (i.e., less than 75,000/mm3); greater than or equal to Grade 2 change in PT and PTT(i.e., 1.5-2x upper level normal (ULN)); greater than or equal to Grade 1 change in AST, ALT (i.e., greater than 2.5x ULN); greater than or equal to Grade 1 change in Bilirubin (i.e., greater than 1.5x ULN); greater than or equal to Grade 1 change in Creatinine (i.e., greater than 2x ULN).